2950-1954

The Journal of Liquid Biopsy

Elsevier

View prefix report (10.1016)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 433 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact433 DOIs
2

Attach ORCID iDs across 316 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact316 DOIs
3

Deposit reference lists for 286 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact286 DOIs

DOIs for this ISSN

Showing the top 5 of 433 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Global requirements for manufacturing and validation of clin… (10.1016/j.jlb.2024.100278)
Abstract ORCID
95.95 82
2 Exosomes Barcoding: A smart approach for cancer liquid biops… (10.1016/j.jlb.2023.100129)
Abstract ORCID
73.12 28
3 Clinical Impact of Multi-omics profiling of extracellular ve… (10.1016/j.jlb.2024.100138)
Abstract ORCID
70.75 25
4 The impact of liquid biopsy in breast cancer: Redefining the… (10.1016/j.jlb.2025.100299)
Abstract ORCID
65.05 19
5 Exploring the clinical utility of liquid biopsy with cfDNA i… (10.1016/j.jlb.2024.100150)
Abstract ORCID
58.80 14
6 Liquid biopsy in gallbladder carcinoma: Current evidence and… (10.1016/j.jlb.2024.100280)
Abstract ORCID
47.71 8
7 Longitudinal Tracking of ALK-positive Lung Cancer From Plasm… (10.1016/j.jlb.2023.100065)
Abstract References ORCID
45.15 3
8 ctDNA-based liquid biopsy reveals wider mutational profile w… (10.1016/j.jlb.2024.100284)
Abstract ORCID
45.15 7
9 Tumor-infiltrating lymphocytes in melanoma: diagnostic and p… (10.1016/j.jlb.2025.100308)
Abstract ORCID
45.15 7
10 Liquid biopsy into the clinics: Current evidence and future… (10.1016/j.jlb.2024.100146)
Abstract
44.98 62
11 Role of cell-free DNA and extracellular vesicles for diagnos… (10.1016/j.jlb.2024.100142)
Abstract ORCID
42.25 6
12 NGS detection of gene rearrangements and METexon14 mutations… (10.1016/j.jlb.2024.100143)
Abstract ORCID
42.25 6
13 Circulating tumor DNA monitoring in advanced mutated melanom… (10.1016/j.jlb.2025.100295)
Abstract ORCID
42.25 6
14 Circulating biomarkers in HPV-associated oropharyngeal cance… (10.1016/j.jlb.2025.100316)
Abstract ORCID
42.25 6
15 Harnessing liquid biopsies: Exosomes and ctDNA as minimally… (10.1016/j.jlb.2023.100126)
Abstract
42.03 47
16 International society of liquid biopsy (ISLB) perspective on… (10.1016/j.jlb.2025.100301)
Abstract
41.09 43
17 Enhancing detection and monitoring of circulating tumor cell… (10.1016/j.jlb.2025.100297)
Abstract
40.05 39
18 Liquid biopsy: Cell-free DNA based analysis in breast cancer (10.1016/j.jlb.2023.100002)
Abstract
37.63 31
19 Circulating miRNAs in genitourinary cancer: pioneering advan… (10.1016/j.jlb.2025.100296)
Abstract
37.63 31
20 Blood and urine-based biomarkers in prostate cancer: Current… (10.1016/j.jlb.2025.100305)
Abstract
37.63 31
21 Liquid Biopsy: Current advancements in clinical practice for… (10.1016/j.jlb.2025.100310)
Abstract
36.93 29
22 Predicting genitourinary cancer tissue-of-origin using urine… (10.1016/j.jlb.2024.100173)
Abstract References ORCID
35.78 2
23 Comprehensive analysis of CTDNA and CTCS reveals resistance… (10.1016/j.jlb.2024.100210)
Abstract References ORCID
35.78 2
24 Liquid biopsy detection of gene Copy Number (CN) losses incl… (10.1016/j.jlb.2024.100221)
Abstract References ORCID
35.78 2
25 The role of molecular biomarkers in the diagnosis, prognosis… (10.1016/j.jlb.2025.100285)
Abstract
35.78 26
26 ALMA platform: a Pan-cancer agnostic multi-modal liquid biop… (10.1016/j.jlb.2025.100337)
Abstract References ORCID
35.78 2
27 Implementation of the clinical practice of liquid biopsies f… (10.1016/j.jlb.2023.100004)
Abstract ORCID
34.95 4
28 Circulating tumor DNA in clinical trials for solid tumors: C… (10.1016/j.jlb.2023.100007)
Abstract
34.95 24
29 Exosomes-based liquid biopsy: An effective approach for drug… (10.1016/j.jlb.2024.100144)
Abstract ORCID
34.95 4
30 Comprehensive analysis of plasma methylome reveals distinct… (10.1016/j.jlb.2024.100159)
Abstract ORCID
34.95 4
31 Circulating tumor DNA kinetics: A future tool for radiation… (10.1016/j.jlb.2024.100160)
Abstract ORCID
34.95 4
32 Circulating tumor DNA profiling for non-invasive genomic ana… (10.1016/j.jlb.2025.100300)
Abstract ORCID
34.95 4
33 Targeted liquid biopsy for brain tumors (10.1016/j.jlb.2024.100170)
Abstract
34.51 23
34 Validity and utility of blood tumor mutational burden (bTMB)… (10.1016/j.jlb.2023.100003)
Abstract
33.56 21
35 Real-time assessment of HER2 status in circulating tumor cel… (10.1016/j.jlb.2023.100117)
Abstract
32.53 19
36 Novel applications of liquid Biopsy: Comprehensive methodolo… (10.1016/j.jlb.2025.100307)
Abstract ORCID
30.10 3
37 Diagnostic value of circulating lncRNAs HOTAIR, ANRIL, and M… (10.1016/j.jlb.2025.100315)
Abstract ORCID
30.10 3
38 Circulating tumor DNA as part of the routine work-up for pat… (10.1016/j.jlb.2025.100443)
Abstract ORCID
30.10 3
39 Unlocking the promise of liquid biopsies in precision oncolo… (10.1016/j.jlb.2024.100151)
Abstract
28.65 13
40 Cellular residual disease (CRD) in early breast cancer –Expa… (10.1016/j.jlb.2023.100132)
Abstract
27.85 12
41 Clinical significance of genomic sequencing of circulating t… (10.1016/j.jlb.2023.100135)
Abstract
27.85 12
42 Roles of Tumor-Educated Platelets (TEPs) in the biology of N… (10.1016/j.jlb.2024.100136)
Abstract
27.85 12
43 Theranostics aspect of extracellular vesicle in cancer liqui… (10.1016/j.jlb.2024.100139)
Abstract
27.85 12
44 Circulating tumor DNA fraction predicts residual cancer burd… (10.1016/j.jlb.2024.100168)
Abstract
27.85 12
45 Expanding the clinical utility of liquid biopsy by using liq… (10.1016/j.jlb.2024.100270)
Abstract
27.85 12
46 Ultrasound mediated blood-brain barrier opening increases br… (10.1016/j.jlb.2024.100277)
Abstract
27.85 12
47 Liquid biopsy for monitoring minimal residual disease in loc… (10.1016/j.jlb.2024.100145)
Abstract
26.98 11
48 The role of liquid biopsy as a catalyst for sustained progre… (10.1016/j.jlb.2024.100156)
Abstract
26.98 11
49 Liquid biopsy through non-blood fluids: The show must go on (10.1016/j.jlb.2024.100272)
Abstract
26.98 11
50 Liquid biopsy in breast cancer: Redefining precision medicin… (10.1016/j.jlb.2025.100312)
Abstract
26.98 11